BXQ-350, An Innovative Asset With Potential For Multiple Indications
BXQ-350 is the foundation of our pipeline and has demonstrated activity in Oncology and CNS. Our pipeline is strategically aligned to our vision of developing best-in-class treatments. There is a critical need for new, safe and effective therapies in Oncology. Bexion is committed to progressing its development through a robust clinical trial program of our novel BXQ-350 franchise.
Multiple Indication Expansion Opportunities in Oncology and CNS